Regulator of calcineurin 1 (RCAN1)

RCAN1, or Regulator of calcineurin 1, is a key endogenous protein inhibitor and modulator of the serine/threonine phosphatase calcineurin (CN), central to calcium-dependent cellular signaling. RCAN1 binds calcineurin via several conserved motifs and inhibits CN activity, affecting processes such as cell proliferation, apoptosis, angiogenesis, immune response, and muscle development. Differential expression and phosphorylation of RCAN1 modulate its inhibitory activity, thus participating in fine-tuning NFAT signaling and broader calcium-responsive gene regulation. Dysregulation of RCAN1 is implicated in numerous diseases, including several cancers (where it can act as an anti-proliferative and anti-angiogenic factor), Alzheimer's disease (where it may contribute to pathology via calcineurin-NFAT mechanisms), Down syndrome (due to its chromosomal location), cardiovascular disease, and degenerative musculoskeletal disorders. RCAN1 is not a receptor or enzyme per se but is classified as a calcineurin-interacting regulatory/modulatory protein. No approved drugs specifically target RCAN1, but it interacts with critical pathways altered by drugs like lenalidomide and other calcineurin inhibitors. RCAN1 gene structure includes several isoforms (notably RCAN1.1 and RCAN1.4), each with potentially distinct biological effects and tissue-specific expression.

Other names

Calcipressin-1ADAPT78CSP1DSC1DSCR1MCIP1Down syndrome critical region protein 1Myocyte-enriched calcineurin-interacting protein 1Down syndrome candidate region 1calcium and oxidant-inducible mRNAmodulatory calcineurin-interacting protein 1near DSCR proline-rich proteinRCN1

Inhibition of calcineurin activity through direct binding competitively blocks substrate recruitment and the active site. Drugs (e.g., lenalidomide) may exert antitumor effects by modulating the CN-NFAT pathway where RCAN1 acts as a negative modulator.